drugset / Trial / NCT01637272
Phase II Study Evaluating Efficacy, Safety and Pharmacokinetics of Pasireotide in Patients With Dumping Syndrome
Non-randomizedSingle-groupOpen-labelTreatment
Summary
multi-center, phase II study evaluating efficacy, safety and pharmacokinetics of pasireotide in patients with dumping syndrome
Timeline
- Start
- 2013-01-08
- Primary completion
- 2015-08-07
- Completion
- 2015-08-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Pasireotide | Other / unclassified | 50 ug | Subcutaneous |
| Subject | Pasireotide | Other / unclassified | 100 ug | Subcutaneous |
| Subject | Pasireotide | Other / unclassified | 150 ug | Subcutaneous |
| Subject | Pasireotide | Other / unclassified | 200 ug | Subcutaneous |
| Subject | Pasireotide | Other / unclassified | 10 mg | Subcutaneous |
| Subject | Pasireotide | Other / unclassified | 20 mg | Subcutaneous |
| Subject | Pasireotide | Other / unclassified | 30 mg | Subcutaneous |
| Subject | Pasireotide | Other / unclassified | 40 mg | Subcutaneous |
| Subject | Pasireotide | Other / unclassified | 60 mg | Subcutaneous |